BIO-TECHNE Corp Q1 FY2027 results
$72.80−0.05%
BIO-TECHNE Corp reported revenue of $300 million, up 4.6% from a year earlier, net income of $28.3 million and diluted earnings per share of $0.18 against $0.24 for the first quarter of fiscal 2027 (the three months to 30 Sep 2026).
From its quarterly report, filed 6 Nov 2026. Compiled and checked by AapWire.
Q1 FY2027 against Q1 FY2026
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q1 FY2027 | Q1 FY2026 | Change |
|---|---|---|---|
| Revenue | $299.7M | $286.6M | +4.6% |
| Gross profit | $196.6M | $188.1M | +4.5% |
| Gross margin | 65.6% | 65.6% | −0.0 pts |
| Operating income | $36.60M | $47.66M | −23.2% |
| Operating margin | 12.2% | 16.6% | −4.4 pts |
| Net income | $28.29M | $38.18M | −25.9% |
| Diluted EPS | $0.18 | $0.24 | −25.0% |
| Operating cash flow | $73.11M | $27.59M | +165% |
| Capital expenditure | $5.92M | $5.36M | +10.3% |
| Free cash flow | $67.20M | $22.22M | +202% |
Operating KPIs for the quarter
| KPI | Q1 FY2027 | Change on a year |
|---|---|---|
| Product and Services revenue | $285.2M | up 1.5% |
| Consumables revenue | $237.3M | up 2.4% |
| Instruments revenue | $25.5M | up 16.8% |
| Services revenue | $22.5M | down 18.3% |
| Royalty revenue | $14.5M | up 156.7% |
| Protein Sciences revenue | $219.7M | up 8.7% |
| Diagnostics and Spatial Biology revenue | $80.2M | up 0.9% |
| United States revenue | $152.7M | down 1.7% |
| EMEA, excluding United Kingdom revenue | $73.9M | up 13.5% |
| China revenue | $28.9M | up 16.6% |
| APAC, excluding Greater China revenue | $22.5M | up 17.3% |
| United Kingdom revenue | $13.7M | up 4.0% |
| Rest of World revenue | $8.1M | down 11.0% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2027 | 30 Sep 2026 | $299.7M | +4.6% | $0.18 |
| Q4 FY2026 | 30 Jun 2026 | $321.2M | +1.3% | $0.35 |
| Q3 FY2026 | 31 Mar 2026 | $311.4M | −1.5% | $0.32 |
| Q2 FY2026 | 31 Dec 2025 | $295.9M | −0.4% | $0.24 |
| Q1 FY2026 | 30 Sep 2025 | $286.6M | −1.0% | $0.24 |
| Q4 FY2025 | 30 Jun 2025 | $317.0M | +3.5% | −$0.11 |
| Q3 FY2025 | 31 Mar 2025 | $316.2M | +4.2% | $0.14 |
| Q2 FY2025 | 31 Dec 2024 | $297.0M | +9.0% | $0.22 |
More on BIO-TECHNE Corp: financial statements · revenue · earnings per share
TECH's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.